Patent application number | Description | Published |
20100003757 | METHODS FOR THE PRODUCTION OF IPS CELLS USING NON-VIRAL APPROACH - Methods and composition of induction of pluripotent stem cells and other desired cell types are disclosed. For example, in certain aspects methods for generating essentially vector-free induced pluripotent stem cells are described. Furthermore, the invention provides induced pluripotent stem cells and desired cell types essentially free of exogenous vector elements with the episomal expression vectors to express differentiation programming factors. | 01-07-2010 |
20100184227 | PLURIPOTENT STEM CELLS OBTAINED BY NON-VIRAL REPROGRAMMING - Methods for reprogramming primate somatic cells to pluripotency using an episomal vector that does not encode an infectious virus are disclosed. Pluripotent cells produced in the methods are also disclosed. | 07-22-2010 |
20120058562 | REPROGRAMMING IMMORTALIZED B CELLS - Methods and composition for providing induced pluripotent stem (iPS) cells are provided. For example, in certain aspects methods including reprogramming B lymphocytes transformed by episomal vectors such as Epstein-Barr virus-based vectors are described. Furthermore, the invention provides induced pluripotent stem cells essentially free of exogenous elements and having B cell immunoglobin variable region rearrangement. | 03-08-2012 |
20120171771 | MODIFIED IPS CELLS HAVING A MUTANT FORM OF A HUMAN IMMUNODEFICIENCY VIRUS (HIV) CELLULAR ENTRY GENE - Methods and composition for generation of genetically modified induced pluripotent stem cells and hematopoietic cell derived therefrom are provided. For example, in certain aspects those cells comprise a modified gene structure related to HIV cellular entry, such as CCR5 mutants. | 07-05-2012 |
20120322670 | IDENTIFYING GENETIC VARIATION IN AFFECTED TISSUES - Methods for the determination of tissue-specific genetic variation are provided. For example, in certain aspects methods for using iPS cell-derived specific cell types for differential molecular analysis of tissue-specific genetic variation are described. | 12-20-2012 |
20130217117 | PLURIPOTENT STEM CELLS OBTAINED BY NON-VIRAL REPROGRAMMING - Methods for reprogramming primate somatic cells to pluripotency using an episomal vector that does not encode an infectious virus are disclosed. Pluripotent cells produced in the methods are also disclosed. | 08-22-2013 |
20130217752 | METHOD OF DERIVING MATURE HEPATOCYTES FROM HUMAN EMBRYONIC STEM CELLS - A method for producing mature hepatocytes having functional hepatic enzyme activity from human pluripotent cells is disclosed. The method includes the step of transferring an external vector comprising the DNA sequence coding for a microRNA having the seed sequence of the microRNA miR-122, the DNA sequence coding for a microRNA having the seed sequence of the microRNA miR-let-7c, a microRNA having the seed sequence of the microRNA miR-122, a microRNA having the seed sequence of the microRNA miR-let-7c, or a combination thereof into one or more fetal hepatocytes. The resulting cells differentiate into mature hepatocytes that exhibit functional hepatic enzyme activity, and can be used in drug metabolism and toxicity testing, in the study of viruses that target hepatic tissue, and as therapeutics. | 08-22-2013 |
20140349397 | REPROGRAMMING IMMORTALIZED B CELLS - Methods and composition for providing induced pluripotent stem (iPS) cells are provided. For example, in certain aspects methods including reprogramming B lymphocytes transformed by episomal vectors such as Epstein-Barr virus-based vectors are described. Furthermore, the invention provides induced pluripotent stem cells essentially free of exogenous elements and having B cell immunoglobin variable region rearrangement. | 11-27-2014 |
20140349405 | RNA-DIRECTED DNA CLEAVAGE AND GENE EDITING BY CAS9 ENZYME FROM NEISSERIA MENINGITIDIS - Disclosed are components and methods for RNA-directed DNA cleavage and gene editing. The components include and the methods utilize a Cas9 protein from | 11-27-2014 |